Press Release: Optimi Health Finalizes Psilocybin Supply Agreement With Bloom Psychedelic Therapy And Research Centre

PRESS RELEASE

VANCOUVER, British Columbia, July 13, 2022 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company cultivating and synthesizing high quality psychedelics and natural functional and psilocybin mushroom strains for transformational human experiences, is pleased to announce that it has finalized a supply agreement with Bloom Psychedelic Therapy And Research Centre (“Bloom”), a Calgary-based provider of mental health services, including psychedelic-assisted therapies employing ketamine treatments.

“Our Supply Agreement with Bloom solidifies another key relationship for Optimi,” said CEO Bill Ciprick. “Their position as therapeutic practitioners, as well as their work in conducting the kind of clinical trials necessary to advance regulatory outcomes for psychedelic medicines, make them ideal partners in alignment with Optimi’s strategic goals.”

Optimi will supply Bloom with sufficient biomass of natural psilocybin to begin conducting its previously announced clinical trial in partnership with the IMPACT Clinical Trial Accelerator Program housed within Alberta’s Life Sciences Innovation Hub at the University of Calgary.

The proposed phase I dosing study will aim to find the optimal microdose or low dose of psilocybin that provides general enhancements to mood, memory, sleep, and other measures of general well-being without any hallucinogenic effects.

Bloom Founder and CEO, Jim Parker, says the partnership between Bloom and Optimi provides an incredible opportunity to measure true GMP-produced, Canadian-sourced natural psilocybin.

“Regulatory bodies in Canada and across the world are watching Canada’s fledgling psychedelics industry and how it performs in quality, safety, and efficacy,” said Parker. “So, I see this as an early watershed moment where good therapeutic practices, combined with Optimi’s Canadian-GMP-grade natural psilocybin, could establish Canada as a real leader amongst those wanting to learn from us.”

Since the completion of its combined 20,000 square feet of psilocybin cultivation and production facilities in Princeton, British Columbia, Optimi has pursued a revenue-focused strategy of clinical therapeutic and research partnerships with the intention of developing logistical channels that will underpin the future of the psychedelics industry.

Read More

https://financialpost.com/globe-newswire/optimi-health-finalizes-psilocybin-supply-agreement-with-bloom-psychedelic-therapy-and-research-centre

Primary Sponsor

 


Karma Koala Podcast

Top Marijuana Blog